Yttrium-90-Ibritumomab Tiuxetan

Yttrium-90-Ibritumomab Tiuxetan

Background: Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin[R]) would result in durable remissions by eliminating minimal residual disease...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology 2018-04, Vol.94 (5)
Hauptverfasser: Heard, Kara, Schatz, Jonathan H, Puvvada, Soham D, Rivera, Xavier I, Anwer, Faiz, Persky, Daniel O, Mahadevan, Daruka, Yan, Jessica, Guillen-Rodrigue, Jose M, Inclan, Lora
Format: Artikel
Sprache:eng
Schlagworte:
Antimitotic agents
Antineoplastic agents
Care and treatment
Clinical trials
Diseases
Methylprednisolone
Non-Hodgkin's lymphomas
Product development
Radioimmunotherapy
Rare earth metals
Relapse
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin[R]) would result in durable remissions by eliminating minimal residual disease after cytoreduction. Methods: Patients with FL received 2 cycles of ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) every 28 days, followed by Zevalin 4-6 weeks later if there was no disease progression and bone marrow biopsy showed
ISSN:0030-2414